title: [Current view on chloroquine derivative treatment from rheumatologist perspective and possible ocular side effects].
abstract: Anti-malarial drugs specifically hydroxychloroquine (HCQ) or chloroquine (CQ) are very effective in treating and preventing the symptoms of systemic lupus erythematosus and other connective tissue diseases. These medications have shown to improve joint and muscle pain and arthritis, skin rashes, fatique, fever and also to control systemic signs of lupus as pericarditis or pleuritis. Shortterm and long-term treatment reduce cholesterol and have anti-platelet effect with decreasing risk of cardiovascular disease. The lupus patients on anti-malarials have also lower risk of cumulative organ damage due to reduce the amount of steroids. They may help to decrease lupus flares, mortality and are the key to controlling lupus long term outcome. Some lupus patients should be on anti-malarials for the rest of their life. For this reason, the key question is weather these drugs are absolutely safe and can be long term used in all lupus patients as a background therapy? Potential non-specific side effects occur very rare and are usually minor and last for short period. The major concerns are retinal deposits damage which could be potential reversible especially during hydroxychloroquine treatment. Nevertheless, ophthalmologist examination is still needed before starting to take HCQ or CQ and at to follow-up visits every 6-12 months. In conclusion it seems that anti-malarials are safe and have more clinical benefits than risks and from rheumatologist point of view should be more widely use in all lupus patients.
authors.affiliation: Department of Rheumatology and Rehabilitation, Laboratory of Metabolic Bone Diseases and Tissue, Medical University, Poznan; Department of Rheumatology and Osteoporosis Hospital, Poznan.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Pawlak-Buś
authors.affiliation: Department of Ophthalmology, Hospital, Poznan; Department of Ophthalmology, University of Warmia and Mazury in Olsztyn.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Gaca-Wysocka
authors.affiliation: Department of Ophthalmology, Hospital, Poznan; Department of Ophthalmology, University of Warmia and Mazury in Olsztyn.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Grzybowski
authors.affiliation: Department of Rheumatology and Rehabilitation, Laboratory of Metabolic Bone Diseases and Tissue, Medical University, Poznan; Department of Rheumatology and Osteoporosis Hospital, Poznan.
authors.forename: Piotr
authors.initials: P
authors.lastname: Leszczyński
mesh_terms: D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use*; D002738:Chloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D012164:Retinal Diseases / Q000139:chemically induced*
chemical_list: D000962:Antimalarials; D006886:Hydroxychloroquine; D002738:Chloroquine
keywords: anti-malarial drugs; side effects; systemic lupus erythematosus; treatment